Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 5, 1997, Pages 834-840

  Bredie, S J H ^a   Van Drongelen, J ^b   Kiemeney, L A ^b   Demacker, P N M ^a   Beaty, T H ^c   Stalenhoef, A F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

apoB; human genetics; lipoproteins

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHILD; CORONARY RISK; FAMILIAL HYPERLIPEMIA; FEMALE; GENE SEGREGATION; GENETIC LINKAGE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PEDIGREE ANALYSIS; PRIORITY JOURNAL;

EID: 0030952459     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.5.834     Document Type: Article

References (15)

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
2. Cullen P, Farren B, Scott J, Farrall M. Complex segregation analysis provides evidence for a major gene acting on serum triglyceride levels in 55 British families with familial combined hyperlipidemia. Arterioscler Thromb. 1994;14:1233-1249.
3. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia: a mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993;92:160-168.
4. Hunt SC, Wu LL, Hopkins PN, Stults BM, Kuida H, Ramirez ME, Lalouel JM, Williams RR. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia: study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis. 1989;9:335-344.
5. Kwiterovich POJ, White S, Forte T, Bachorik PS, Smith H, Sniderman A. Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholesterolemia. Arteriosclerosis. I987;7:211-225.
6. Kwiterovich POJ. Genetics and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidol. 1993;4:133-143.
7. Kissebah AH, Alfarsi S, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism. 1981;30:856-868.
8. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemi-cally coherent basis for familial combined hyperlipidemia. Arterioscler Thromb. 1993;13:1110-1118.
9. Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb. 1992;12:1176-1183.
10. Hoffer MJ, Bredie SJH, Boomsma DI, Reymer PWA, Kastelein JJP, de Knijff P, Demacker PNM, Stalenhoef AFH, Havekes LM, Frants RR. The lipoprotein lipase (Asn291-Ser) mutation is associated with elevated lipid levels in familial combined hyperlipidemia. Atherosclerosis. 1996;119:159-167.
11. Brunzell JD, Chait A, Albers JJ, Foster DM, Failor RA, Bierman EL. Metabolic consequences of genetic heterogeneity of lipoprotein composition (lipoprotein heterogeneity). Am Heart J. 1987;113:583-588.
12. Stalenhoef AFH, Demacker PNM, Lutterman JA, van't Laar A. Plasma lipoproteins, apolipoproteins, and triglyceride metabolism in familial hypertriglyceridemia. Arteriosclerosis. 1986;6:387-394.
13. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis. 1987;7:203-207.
14. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
15. Kwiterovich POJ, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged ≤50 years) and women (≤60 years) with coronary artery disease. Am J Cardiol. 1993;71:631-639.